<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MINIPRESS- prazosin hydrochloride capsule </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<h1>Minipress® <br>Capsules<br> (prazosin hydrochloride)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold Italics">For Oral Use</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">MINIPRESS® (prazosin hydrochloride), a quinazoline derivative, is the first of a new chemical class of antihypertensives. It is the hydrochloride salt of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl) piperazine and its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc&amp;name=minipress-01.jpg"></div>
<p>Molecular formula C<span class="Sub">19</span>H<span class="Sub">21</span>N<span class="Sub">5</span>O<span class="Sub">4</span>•HCl</p>
<p>It is a white, crystalline substance, slightly soluble in water and isotonic saline, and has a molecular weight of 419.87. Each 1 mg capsule of MINIPRESS for oral use contains drug equivalent to 1 mg free base.</p>
<p>Inert ingredients in the formulations are: hard gelatin capsules (which may contain Blue 1, Red 3, Red 28, Red 40, and other inert ingredients); magnesium stearate; sodium lauryl sulfate; starch; sucrose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Recent animal studies, however, have suggested that the vasodilator effect of prazosin is also related to blockade of postsynaptic alpha-adrenoceptors. The results of dog forelimb experiments demonstrate that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional alpha-blockers, the antihypertensive action of prazosin is usually not accompanied by a <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span>. Tolerance has not been observed to develop in long term therapy.</p>
<p>Hemodynamic studies have been carried out in man following acute single dose administration and during the course of long term maintenance therapy. The results confirm that the therapeutic effect is a <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> unaccompanied by a clinically significant change in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, heart rate, renal blood flow and glomerular filtration rate. There is no measurable negative chronotropic effect.</p>
<p>In clinical studies to date, prazosin hydrochloride has not increased plasma renin activity.</p>
<p>In man, blood pressure is lowered in both the supine and standing positions. This effect is most pronounced on the diastolic blood pressure.</p>
<p>Following oral administration, human plasma concentrations reach a peak at about three hours with a plasma half-life of two to three hours. The drug is highly bound to plasma protein. Bioavailability studies have demonstrated that the total absorption relative to the drug in a 20% alcoholic solution is 90%, resulting in peak levels approximately 65% of that of the drug in solution. Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man.</p>
<p>In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre-  and post-treatment lipid levels.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">MINIPRESS is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug.</p>
<p>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</p>
<p>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but reductions in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and cardiovascular mortality also have been seen regularly.</p>
<p>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (for example, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</p>
<p>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or diabetic kidney disease). These considerations may guide selection of therapy.</p>
<p>MINIPRESS can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">MINIPRESS is contraindicated in patients with known sensitivity to quinazolines, prazosin, or any of the inert ingredients.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">As with all alpha-blockers, MINIPRESS may cause <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> with sudden <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. In most cases, this is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by a bout of severe <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> with heart rates of 120–160 beats per minute. Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of MINIPRESS. The  incidence of syncopal episodes is approximately 1% in patients given an initial dose of 2 mg or greater. Clinical trials conducted during the investigational phase of this drug suggest that syncopal episodes can be minimized by limiting the initial dose of the drug to 1 mg, by subsequently increasing the dosage slowly, and by introducing any additional antihypertensive drugs into the patient's regimen with caution (see <a href="#Dosage_and_Administration">DOSAGE AND ADMINISTRATION)</a>. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may develop in patients given MINIPRESS who are also receiving a beta-blocker such as propranolol.</span></p>
<p>If <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, the patient should be placed in the recumbent position and treated supportively as necessary. This adverse effect is self-limiting and in most cases does not recur after the initial period of therapy or during subsequent dose titration.</p>
<p>Patients should always be started on the 1 mg capsules of MINIPRESS. The 2 and 5 mg capsules are not indicated for initial therapy.</p>
<p>More common than <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> are the symptoms often associated with lowering of the blood pressure, namely, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>. The patient should be cautioned about these possible adverse effects and advised what measures to take should they develop. The patient should also be cautioned to avoid situations where injury could result should <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occur during the initiation of MINIPRESS therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></h2>
<p class="First">Prolonged erections and <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> have been reported with alpha-1 blockers including prazosin in post marketing experience. In the event of an erection that persists longer than 4 hours, seek immediate medical assistance. If <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> is not treated immediately, penile tissue damage and permanent loss of potency could result.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436397" conceptname="Intraoperative floppy iris syndrome">Intraoperative Floppy Iris Syndrome</span> (IFIS) has been observed during <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery in some patients treated with alpha-1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient's ophthalmologist should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.  </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may occur after the first dose of this medicine. Avoid driving or performing hazardous tasks for the first 24 hours after taking this medicine or when the dose is increased. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> may occur, especially when rising from a lying or sitting position. Getting up slowly may help lessen the problem. These effects may also occur if you drink alcohol, stand for long periods of time, exercise, or if the weather is hot. While taking MINIPRESS, be careful in the amount of alcohol you drink. Also, use extra care during exercise or hot weather, or if standing for long periods. Check with your physician if you have any questions.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">MINIPRESS has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac  glycosides–digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see <a href="#Warnings">WARNINGS</a> however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories–propoxyphene, aspirin, indomethacin, and phenylbutazone.</p>
<p>Addition of a diuretic or other antihypertensive agent to MINIPRESS has been shown to cause an additive hypotensive effect. This effect can be minimized by reducing the MINIPRESS dose to 1 to 2 mg three times a day, by introducing additional antihypertensive drugs cautiously, and then by retitrating MINIPRESS based on clinical response.</p>
<p>Concomitant administration of MINIPRESS with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (see <a href="#Dosage_and_Administration">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">In a study on five patients given from 12 to 24 mg of prazosin per day for 10 to 14 days, there was an average increase of 42% in the urinary metabolite of norepinephrine and an average increase in urinary VMA of 17%. Therefore, false positive results may occur in screening tests for <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> in patients who are being treated with prazosin. If an elevated VMA is found, prazosin should be discontinued and the patient retested after a month.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.5"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre-  and post-treatment lipid levels.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenic potential was demonstrated in an 18 month study in rats with MINIPRESS at dose levels more than 225 times the usual maximum recommended human dose of 20 mg per day. MINIPRESS was not mutagenic in <span class="Italics">in vivo</span> genetic toxicology studies. In a fertility and general reproductive performance study in rats, both males and females, treated with 75 mg/kg (225 times the usual maximum recommended human dose), demonstrated decreased fertility, while those treated with 25 mg/kg (75 times the usual maximum recommended human dose) did not.</p>
<p>In chronic studies (one year or more) of MINIPRESS in rats and dogs, testicular changes consisting of <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> occurred at 25 mg/kg/day (75 times the usual maximum recommended human dose). No testicular changes were seen in rats or dogs at 10 mg/kg/day (30 times the usual maximum recommended human dose). In view of the testicular changes observed in animals, 105 patients on long term MINIPRESS therapy were monitored for 17-ketosteroid excretion and no changes indicating a drug effect were observed. In addition, 27 males on MINIPRESS for up to 51 months did not have changes in sperm morphology suggestive of drug effect.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.7"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Pregnancy Category C. MINIPRESS has been shown to be associated with decreased litter size at birth, 1, 4, and 21 days of age in rats when given doses more than 225 times the usual maximum recommended human dose. No evidence of drug-related external, visceral, or skeletal fetal abnormalities were observed. No drug-related external, visceral, or skeletal abnormalities were observed in fetuses of pregnant rabbits and pregnant monkeys at doses more than 225 times and 12 times the usual maximum recommended human dose, respectively.</p>
<p>The use of prazosin and a beta-blocker for the control of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in 44 pregnant women revealed no drug-related fetal abnormalities or adverse effects. Therapy with prazosin was continued for as long as 14 weeks.<span class="Sup">1</span></p>
<p>Prazosin has also been used alone or in combination with other hypotensive agents in severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> of pregnancy by other investigators. No fetal or neonatal abnormalities have been reported with the use of prazosin.<span class="Sup">2</span></p>
<p>There are no adequate and well controlled studies which establish the safety of MINIPRESS in pregnant women. MINIPRESS should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">MINIPRESS has been shown to be excreted in small amounts in human milk. Caution should be exercised when MINIPRESS is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Usage in Children</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Clinical trials were conducted on more than 900 patients. During these trials and subsequent marketing experience, the most frequent reactions associated with MINIPRESS therapy are: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> 10.3%, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> 7.8%, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> 7.6%, lack of energy 6.9%, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> 6.5%, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> 5.3%, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> 4.9%. In most instances, side effects have disappeared with continued therapy or have been tolerated with no decrease in dose of drug.</p>
<p>Less frequent adverse reactions which are reported to occur in 1–4% of patients are:</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>.</p>
<p><span class="Italics">Dermatologic:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p><span class="Italics">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>.</p>
<p><span class="Italics">EENT:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, reddened sclera, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>.</p>
<p>In addition, fewer than 1% of patients have reported the following (in some instances, exact causal relationships have not been established):</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, liver function abnormalities, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>.</p>
<p><span class="Italics">Dermatologic:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>.</p>
<p><span class="Italics">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>.</p>
<p><span class="Italics">EENT:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Italics">Other:</span> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, positive ANA titer, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>.</p>
<p>Single reports of pigmentary mottling and serous <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>, and a few reports of <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> development or disappearance have been reported. In these instances, the exact causal relationship has not been established because the baseline observations were frequently inadequate.</p>
<p>In more specific slit-lamp and funduscopic studies, which included adequate baseline examinations, no drug-related abnormal ophthalmological findings have been reported.</p>
<p>Literature reports exist associating MINIPRESS therapy with a worsening of pre-existing <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>. A causal relationship is uncertain in these cases.</p>
<p>In post-marketing experience, the following adverse events have been reported:</p>
<p><span class="Italics">Autonomic Nervous System:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>.</p>
<p><span class="Italics">Body As A Whole:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Italics">Cardiovascular, General:</span> <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p><span class="Italics">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.</p>
<p><span class="Italics">Heart Rate/Rhythm:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p><span class="Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Italics">Skin/Appendages:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Vascular (Extracardiac):</span> <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Italics">Vision:</span> <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>.</p>
<p><span class="Italics">Special Senses: </span> During <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery, a variant of small pupil syndrome known as <span class="product-label-link" type="condition" conceptid="436397" conceptname="Intraoperative floppy iris syndrome">Intraoperative Floppy Iris Syndrome</span> (IFIS) has been reported in association with alpha-1 blocker therapy (see <a href="#PRECAUTIONS">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Accidental ingestion of at least 50 mg of MINIPRESS in a two year old child resulted in profound <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and depressed reflexes. No decrease in blood pressure was noted. Recovery was uneventful. </p>
<p>Should overdosage lead to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> should first be treated with volume expanders. If necessary, vasopressors should then be used. Renal function should be monitored and supported as needed. Laboratory data indicate MINIPRESS is not dialysable because it is protein bound.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Dosage_and_Administration"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose of MINIPRESS should be adjusted according to the patient's individual blood pressure response. The following is a guide to its administration:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Initial Dose</h2>
<p class="First">1 mg two or three times a day (see <a href="#Warnings">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Maintenance Dose</h2>
<p class="First">Dosage may be slowly increased to a total daily dose of 20 mg given in divided doses. The therapeutic dosages most commonly employed have ranged from 6 mg to 15 mg daily given in divided doses. Doses higher than 20 mg usually do not increase efficacy, however a few patients may benefit from further increases up to a daily dose of 40 mg given in divided doses. After initial titration some patients can be maintained adequately on a twice daily dosage regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Use With Other Drugs</h2>
<p class="First">When adding a diuretic or other antihypertensive agent, the dose of MINIPRESS should be reduced to 1 mg or 2 mg three times a day and retitration then carried out. </p>
<p>Concomitant administration of MINIPRESS with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking MINIPRESS.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table width="75%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="left" valign="middle" width="20%">
<thead><tr class="First Last">
<th class="Botrule Lrule" align="center">Strength</th>
<th class="Botrule Lrule" align="center">Capsule Color</th>
<th class="Botrule Lrule" align="center">Capsule Code</th>
<th class="Botrule Lrule" align="center">NDC</th>
<th class="Botrule Lrule Rrule" align="center">Package Size</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center">MINIPRESS® 1 mg</td>
<td class="Botrule Lrule" align="center">White</td>
<td class="Botrule Lrule" align="center">431</td>
<td class="Botrule Lrule" align="center">0069-4310-71</td>
<td class="Botrule Lrule Rrule" align="left">250's</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">MINIPRESS® 2 mg</td>
<td class="Botrule Lrule" align="center">Pink and White</td>
<td class="Botrule Lrule" align="center">437</td>
<td class="Botrule Lrule" align="center">0069-4370-71</td>
<td class="Botrule Lrule Rrule" align="left">250's</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">MINIPRESS® 5 mg</td>
<td class="Botrule Lrule" align="center">Blue and White</td>
<td class="Botrule Lrule" align="center">438</td>
<td class="Botrule Lrule" align="center">0069-4380-71</td>
<td class="Botrule Lrule Rrule" align="left">250's</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>References</h1>
<ol>
<li> Lubbe, WF, and Hodge, JV: <span class="Italics">New Zealand Med J</span>, <span class="Bold">94</span> (691) 169–172, 1981.</li>
<li> Davey, DA, and Dommisse, J: <span class="Italics">S.A. Med J</span>, Oct. 4, 1980 (551–556).</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc&amp;name=minipress-02.jpg"></p>
<p>LAB-0212-6.0<br>February 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mg Capsule Bottle Label</h1>
<p class="First"><span class="Bold Italics">Pfizer</span><br>NDC 0069-4310-71</p>
<p><span class="Bold">Minipress</span><span class="Sup">®</span><br>(prazosin hydrochloride)</p>
<p><span class="Bold">1 mg*<br>Capsules</span></p>
<p>250 Capsules<br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 mg Capsule Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc&amp;name=minipress-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2 mg Capsule Bottle Label</h1>
<p class="First"><span class="Bold Italics">Pfizer</span><br>NDC 0069-4370-71</p>
<p><span class="Bold">Minipress</span><span class="Sup">®</span><br>(prazosin hydrochloride)</p>
<p><span class="Bold">2 mg*<br>Capsules</span></p>
<p>250 Capsules<br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2 mg Capsule Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc&amp;name=minipress-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg Capsule Bottle Label</h1>
<p class="First"><span class="Bold Italics">Pfizer</span><br>NDC 0069-4380-71</p>
<p><span class="Bold">Minipress</span><span class="Sup">®</span><br>(prazosin hydrochloride)</p>
<p><span class="Bold">5 mg*<br>Capsules</span></p>
<p>250 Capsules<br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg Capsule Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc&amp;name=minipress-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MINIPRESS 		
					</strong><br><span class="contentTableReg">prazosin hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-4310</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PRAZOSIN HYDROCHLORIDE</strong> (PRAZOSIN) </td>
<td class="formItem">PRAZOSIN</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;431;Minipress</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-4310-71</td>
<td class="formItem">250  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017442</td>
<td class="formItem">05/10/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MINIPRESS 		
					</strong><br><span class="contentTableReg">prazosin hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-4370</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PRAZOSIN HYDROCHLORIDE</strong> (PRAZOSIN) </td>
<td class="formItem">PRAZOSIN</td>
<td class="formItem">2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE, PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;437;Minipress</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-4370-71</td>
<td class="formItem">250  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017442</td>
<td class="formItem">05/10/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MINIPRESS 		
					</strong><br><span class="contentTableReg">prazosin hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-4380</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PRAZOSIN HYDROCHLORIDE</strong> (PRAZOSIN) </td>
<td class="formItem">PRAZOSIN</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE, BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;438;Minipress</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-4380-71</td>
<td class="formItem">250  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017442</td>
<td class="formItem">05/10/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Ireland Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">896090987</td>
<td class="formItem">ANALYSIS(0069-4380, 0069-4370, 0069-4310), API MANUFACTURE(0069-4380, 0069-4370, 0069-4310)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084552</td>
<td class="formItem">PACK(0069-4380, 0069-4370, 0069-4310)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084545</td>
<td class="formItem">ANALYSIS(0069-4380, 0069-4370, 0069-4310), API MANUFACTURE(0069-4380, 0069-4370, 0069-4310), MANUFACTURE(0069-4380, 0069-4370, 0069-4310), PACK(0069-4380, 0069-4370, 0069-4310)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>54db6256-af93-4b94-b2d9-faafffdc8998</div>
<div>Set id: 36c4da56-502e-4da1-acf7-8e81ee453dcc</div>
<div>Version: 9</div>
<div>Effective Time: 20150421</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
